RECRUITING

All-extremity Exercise During Breast Cancer Chemotherapy

Description

Currently, there are 3.5 million breast cancer survivors in the United States and this number is expected to increase dramatically. The proposed research will examine whether a novel exercise intervention for breast cancer patients who are undergoing chemotherapy protects against cardiovascular dysfunction. Findings may have implications for cardiovascular disease prevention in this population.

Conditions

Breast Cancer
Talk to us

Related Conditions:

Breast Cancer

Study Overview

On this page

Study Details

Study overview

Currently, there are 3.5 million breast cancer survivors in the United States and this number is expected to increase dramatically. The proposed research will examine whether a novel exercise intervention for breast cancer patients who are undergoing chemotherapy protects against cardiovascular dysfunction. Findings may have implications for cardiovascular disease prevention in this population.

All-extremity Exercise as a Novel Strategy for Optimizing Cardiovascular Function During Chemotherapy for Breast Cancer

All-extremity Exercise During Breast Cancer Chemotherapy

Condition
Breast Cancer
Intervention / Treatment

-

Contacts and Locations

Gainesville

Integrative Cardiovasculal Physiology Laboratory, University of Florida, Gainesville, Florida, United States, 32611

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

For general information about clinical research, read Learn About Studies.

Eligibility Criteria

  • * Active diagnosis of primary invasive non-metastatic breast cancer, stages I-III
  • * Female
  • * 18 to 85 years of age
  • * Scheduled to initiate neoadjuvant or adjuvant chemotherapy (anthracycline, alkylating agent and/or taxane)
  • * Absence of contraindications to exercise
  • * Study clinician approval
  • * Able to give consent
  • * Informed consent obtained from the subject and documentation of subject agreement to comply with study-related process
  • * Do not meet inclusion criteria
  • * Receiving targeted therapies (CDK4/6 or PARP inhibitors)
  • * Receiving radiation therapy concurrent with chemotherapy
  • * Lymphedema stage ≥ 2 prior to study enrollment
  • * Any relevant cardiovascular diseases (stroke, heart failure, myocardial ischemia during maximal graded exercise test, myocardial infarction, angina pectoris, coronary artery bypass surgery or angioplasty or coronary stent)
  • * Current participation in other experimental interventions that may confound interpretation of study findings (e.g., dietary intervention for weight loss)

Ages Eligible for Study

18 Years to 85 Years

Sexes Eligible for Study

FEMALE

Accepts Healthy Volunteers

No

Collaborators and Investigators

University of Florida,

Demetra Christou, PhD, PRINCIPAL_INVESTIGATOR, University of Florida

Study Record Dates

2026-05-31